NewAmsterdam Pharma Co NV (STU:KH6) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:KH6 NewAmsterdam Pharma Co NV STU:KH6
44 GF Score
Price €23.45
GF Value €10.04
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV SpecialCharges?

Special Charges only applies to banks.

STU:KH6
44GF Score
NewAmsterdam Pharma Co NV STU:KH6
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NewAmsterdam Pharma Co NV (STU:KH6) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of €23.45 is trading 133.6% above its estimated GF Value™ of €10.04. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for STU:KH6:

  • SpecialCharges:
  • GF Value™: €10.04 vs. price of €23.45 (133.6% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the STU:KH6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NewAmsterdam Pharma Co NV Business Description

Other Exchanges NAMS:USA
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
44GF Score

Get the complete analysis for STU:KH6

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.45
Price
€10.04
GF Value